Back to Search
ELIANE JABBOUR ATALLAH MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1477303873Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (17)
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
PMID 19445582·Expert Rev Anticancer Ther·2009
6-review
Practical considerations for the management of patients in the tyrosine kinase inhibitor era.
PMID 19621545·Semin Hematol·2009
8-other
Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
PMID 19654496·J Clin Rheumatol·2009
5-case
Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
PMID 19394693·Leuk Res·2009
5-case
Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
PMID 18059483·Leukemia·2008
8-other
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
PMID 17673605·Blood·2007
8-other
Use of hypomethylating agents in myelodysplastic syndromes.
PMID 17679928·Clin Adv Hematol Oncol·2007
6-review
Congestive heart failure is a rare event in patients receiving imatinib therapy.
PMID 17449798·Blood·2007
8-other
Agent Orange, prostate cancer irradiation and acute promyelocyic leukemia (APL): is there a link?
PMID 16956658·Leuk Res·2007
5-case
The role of decitabine in the treatment of myelodysplastic syndromes.
PMID 17163808·Expert Opin Pharmacother·2007
6-review
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
PMID 17206119·Nat Med·2007
8-other
Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
PMID 17255791·Curr Opin Hematol·2007
6-review
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
PMID 17382019·Clin Lymphoma Myeloma·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 462 GRIDER ST
BUFFALO, NY 14215 - Phone
- (716) 898-4578
Quick Facts
- NPI
- 1477303873
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 17
Are you this provider?
Claim Your Profile